Search
Tirzepatide Treatment Options in Las Vegas, NV
A collection of 16 research studies where Tirzepatide is the interventional treatment. These studies are located in the Las Vegas, NV. Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
1 - 12 of 16
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Completed
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/22/2025
Locations: Palm Research Center Tenaya, Las Vegas, Nevada +1 locations
Conditions: Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Completed
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/15/2025
Locations: Palm Research Center Tenaya, Las Vegas, Nevada
Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Active Not Recruiting
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab.
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Las Vegas Dermatology, Las Vegas, Nevada +1 locations
Conditions: Psoriasis, Obesity
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: Las Vegas Medical Research, Las Vegas, Nevada
Conditions: Obesity, Overweight
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/17/2025
Locations: Las Vegas Medical Research, Las Vegas, Nevada
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Palm Research Center Tenaya, Las Vegas, Nevada +1 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Completed
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Palm Research Center Sunset, Las Vegas, Nevada
Conditions: Overweight, Obesity
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Active Not Recruiting
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/01/2025
Locations: DaVita Clinical Research - Las Vegas, Las Vegas, Nevada +4 locations
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
Completed
The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk. The study drug was given as a single injection under the skin in healthy lactating females. For each participant, the total duration of the study was approximately 8 weeks, including screening.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Las Vegas Clinical Research Unit - PPD, Las Vegas, Nevada
Conditions: Healthy
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Not Yet Recruiting
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Populace Health, LLC - Vector Clinical Trials, Las Vegas, Nevada
Conditions: Obesity and Overweight
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Completed
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Clinical Research of South Nevada, Las Vegas, Nevada +1 locations
Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Palm Research Center Tenaya, Las Vegas, Nevada +1 locations
Conditions: Obesity, Overweight
1 - 12 of 16